MK-677, or ibutamoren, is one of the most-hyped compounds in biohacking and gym content, marketed as an oral, needle-free way to boost growth hormone for muscle, recovery, skin and — increasingly — sleep. Mechanistically it is a non-peptide ghrelin-receptor agonist (a growth-hormone secretagogue) that raises pulsatile GH and IGF-1, and studies do show it increases slow-wave (deep) sleep and lean body mass. Those real effects, appearing within days for appetite and sleep, are what drive the anecdotes.
The problem is the safety record from the trials that were actually run. A multicentre phase II study in elderly patients recovering from hip fracture was terminated early after a higher rate of congestive heart failure in the ibutamoren group than placebo. Across aging, Alzheimer's and hip-fracture programmes, the compound reliably raised IGF-1 and muscle mass but failed to improve functional outcomes such as walking speed — and Merck ultimately discontinued development. MK-677 has never been approved for any indication.
Beyond the cardiac signal, MK-677 consistently worsens glucose control. Trials report elevated fasting glucose, reduced insulin sensitivity and rising HbA1c, a predictable consequence of chronically elevated GH/IGF-1. Users also commonly report water retention, joint pain and transient carpal-tunnel-like nerve symptoms as fluid accumulates in connective tissue.
The gap between the trend and the evidence is about population and duration. The 'better sleep and recovery' most social posts describe are short-term, subjective and often in young healthy people; the documented harms — heart failure in a vulnerable group, measurable metabolic deterioration — come from controlled trials and are why a major pharmaceutical company walked away. Long-term safety in healthy adults simply has not been studied.